#ePathology

[dpathucgconforences]

Final call for delegates!! The 11th World Digital Pathology & AI UCGCongress from December 15-17, 2023, in Holiday Inn Dubai, Al Barsha, UAE & Virtual. WhatsApp us: https://wa.me/442033222718?text= In-person Register link here: https://digitalpathology.ucgconferences.com/registration/

[shelcywalters-blog]

Surgical Pathology 2019 – Paris is a great opportunity to explore your idea @ surgicalpathology.alliedacademies.com

[healthcare-research-report-blog]

Anatomic Pathology Testing market | Quantitative Analysis, Current and Future Trends, 2025

Anatomic pathology, or anatomical pathology, entails biochemical, microscopic, and molecular examination of tissues and organs to uncover abnormalities in them. This helps to diagnose diseases and manage treatment. Although most commonly used to detect and manage different kinds of cancer and tumors, it is also useful in evaluating other health conditions such as kidney and liver diseases, infections, and autoimmune diseases.

The two different types of anatomic pathology testing products are instruments and consumables. Instruments include slides, microscope, centrifuges, and cassette printers, while consumables include reagents, kits, and antibodies. The two different services in the Anatomic Pathology Testing Market are cytopathology and histopathology. Anatomic pathology testing finds application in hospitals, clinical diagnostic laboratories, and physician office laboratories.

From a geographical standpoint, North America is a key region in the anatomic pathology testing market because of the growing prevalence of cancer and other chronic diseases. Europe is another key region and is propelled by the large pool of elderly population that is highly susceptible to chronic diseases and surging popularity of personalized medicine and digital laboratory.

Asia Pacific is a lucrative market owing to the rising investment by governments and academic institutions in diagnostic research and increasing awareness about anatomic pathology tests. In addition, globalization, improving economies, and changing lifestyle is also stoking growth in the market in the region.

Some of the prominent participants in the global anatomic pathology testing market are Neogenomics Laboratories, Inc., Abbott Diagnostic International Ltd., Danaher, Agilent Technologies, Bio SB, Roche Diagnostics, and Quest Diagnostics Incorporated.

 Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26852

 Anatomic pathology is a branch of science or branch of medicine that primarily involves microscopic, biochemical, and molecular examination of organs and tissues to find out the effectiveness of diseases. The key objective of anatomic pathology is to identify abnormalities in order to manage diagnosis and treatment. Anatomic pathology helps to detect various types of tumor and cancer. It is also sometimes useful to evaluate the liver and kidney diseases effectively. Gross examination, histopathology, immunohistochemistry, cytopathology, and flow immunophenotyping are some of the procedures carried out during anatomic pathology test. Anatomic pathology testing is a superspeciality test. To perform this type of test, a person should have a qualified certification from a recognized body such as the American Board of Pathology or the American Osteopathic Board of Pathology. Anatomic pathologist is also involved in post mortem examination. Like clinical pathology reports, anatomic pathology reports also contain essential elements such as name, number, sample type, and source. Many anatomic pathology departments operate according to the specific need of a patient.

The anatomic pathology testing market has been segmented based on product, services, and application. In terms of product, the market has been categorized into instruments and consumables. Instruments such as microscope, centrifuges, slides, and cassette printers are used to conduct anatomic pathology tests. Consumables include kits, reagents, and antibodies. Based on services, the anatomic pathology testing market has been segmented into cytopathology and histopathology. In terms of application, the market has been categorized into breast cancer diagnosis, lung cancer diagnosis, and cervical cancer diagnosis. Based on end-user, the global anatomic pathology testing market has been segmented into clinical diagnostic laboratories, hospitals, and physician office laboratories. Increasing prevalence of chronic diseases, maximum use of biomarkers, direct to customer facility, and government awareness about early cancer detection and diagnosis are likely to boost the growth of the anatomic pathology testing market. High cost of digital imaging, poor resolution, set up costs, lack of depth perception are some of the factors restraining the market.

Geographically, the anatomic pathology testing market is dominated by North America due to rising incidence of cancer and epathology solutions. Rising prevalence of chronic diseases, rapid increase in geriatric population, and high acceptance of personalized medicine and digital laboratory propel the market in Europe. Growing academic and government investment in diagnostic research and rising awareness about the use of anatomic pathology test among physicians are projected to boost the growth of the market in Asia Pacific. Increasing globalization, sound economy, and changing lifestyle habits of the population in the region has led to the growth of the anatomy pathology testing market in Latin America. High life expectancy, increasing burden of diseases, increasing chronic and non-communicable diseases such as diabetes, cancer, and obesity fuel the growth of the anatomic pathology testing market. Improving living standards, and increasing demand for quality medicines in Middle East & Africa boost the growth of the anatomy pathology testing market in the region.

Major players in the anatomic pathology testing market are Abbott Diagnostic International Ltd., Agilent Technologies, Danaher, Roche Diagnostics, Bio SB, Neogenomics Laboratories, Inc., and Quest Diagnostics Incorporated.

 Enquiry for discount on this report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26852

 About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

 US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

[treatmentdisease-blog]

New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment

New Post has been published on http://bit.ly/2Elppg8

Epathologies observation sarcoma cancer ribbon

[healthy-insights]

Anatomic Pathology Testing market Research Report: Forecast up to 2025

Anatomic pathology is a branch of science or branch of medicine that primarily involves microscopic, biochemical, and molecular examination of organs and tissues to find out the effectiveness of diseases. The key objective of anatomic pathology is to identify abnormalities in order to manage diagnosis and treatment. Anatomic pathology helps to detect various types of tumor and cancer. It is also sometimes useful to evaluate the liver and kidney diseases effectively. Gross examination, histopathology, immunohistochemistry, cytopathology, and flow immunophenotyping are some of the procedures carried out during anatomic pathology test. Anatomic pathology testing is a superspeciality test. To perform this type of test, a person should have a qualified certification from a recognized body such as the American Board of Pathology or the American Osteopathic Board of Pathology. Anatomic pathologist is also involved in post mortem examination. Like clinical pathology reports, anatomic pathology reports also contain essential elements such as name, number, sample type, and source. Many anatomic pathology departments operate according to the specific need of a patient.

The anatomic pathology testing market has been segmented based on product, services, and application. In terms of product, the market has been categorized into instruments and consumables. Instruments such as microscope, centrifuges, slides, and cassette printers are used to conduct anatomic pathology tests. Consumables include kits, reagents, and antibodies. Based on services, the anatomic pathology testing market has been segmented into cytopathology and histopathology. In terms of application, the market has been categorized into breast cancer diagnosis, lung cancer diagnosis, and cervical cancer diagnosis. Based on end-user, the global anatomic pathology testing market has been segmented into clinical diagnostic laboratories, hospitals, and physician office laboratories. Increasing prevalence of chronic diseases, maximum use of biomarkers, direct to customer facility, and government awareness about early cancer detection and diagnosis are likely to boost the growth of the anatomic pathology testing market. High cost of digital imaging, poor resolution, set up costs, lack of depth perception are some of the factors restraining the market.

View Report-

http://www.transparencymarketresearch.com/anatomic-pathology-testing-market.html

 Geographically, the anatomic pathology testing market is dominated by North America due to rising incidence of cancer and epathology solutions. Rising prevalence of chronic diseases, rapid increase in geriatric population, and high acceptance of personalized medicine and digital laboratory propel the market in Europe. Growing academic and government investment in diagnostic research and rising awareness about the use of anatomic pathology test among physicians are projected to boost the growth of the market in Asia Pacific. Increasing globalization, sound economy, and changing lifestyle habits of the population in the region has led to the growth of the anatomy pathology testing market in Latin America. High life expectancy, increasing burden of diseases, increasing chronic and non-communicable diseases such as diabetes, cancer, and obesity fuel the growth of the anatomic pathology testing market. Improving living standards, and increasing demand for quality medicines in Middle East & Africa boost the growth of the anatomy pathology testing market in the region.

Major players in the anatomic pathology testing market are Abbott Diagnostic International Ltd., Agilent Technologies, Danaher, Roche Diagnostics, Bio SB, Neogenomics Laboratories, Inc., and Quest Diagnostics Incorporated.

Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Anatomic Pathology Testing market during 2017- 2025

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26852

 About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

 US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

[healthcarebiz]

Leica Biosystems Aperio Digital Pathology Now Nationwide Standard of Care in Kuwait*

VISTA, Calif., May 23, 2017 /PRNewswire/ -- Leica Biosystems announced today that it has struck a key partnership with the Kuwait Ministry of Health, through its distributor, Technical Services Supplies Trading & Contracting Company, W.L.L. The Pathology Council of Kuwait will now adopt Leica Biosystems digital pathology as its standard of care. This initiative will create a nationwide pathology network, powered by Aperio ePathology Solutions, linking eight key hospitals and leveraging pathology expertise across the country.

"With one of the most extensive digital pathology initiatives in the world, Kuwait is leading the charge to transform pathology and its critical role in healthcare," said Jerome Clavel, Vice President and General Manager for Leica Biosystems Pathology Imaging. "Our Aperio ePathology Solutions will enable rapid sharing and collaboration. This will reduce the need for pathologists to travel and increase patient access especially in remote locations."

The Kuwait Cancer Control Center (KCCC) has been using Aperio ePathology since 2011, for both national and international slide sharing and collaboration. Building on their experience, the nationwide hub-and-spoke deployment of Aperio ePathology will enable efficient utilization of Kuwait's pathology expertise; providing pathologists with rapid access to slides and cases.

"The full adoption of Aperio ePathology throughout Kuwait is a critical, technological advancement for the pathology workflow. It will make secondary reviews and collaboration easier, faster and more efficient. In the past, shipping of glass slides required 3 to 4 days by itself. Now, subspecialty expertise can be available to remote locations within 24 hours without sending any physical slides," said Dr. Abdullah Akbar, Consultant Pathologist, Head of the Laboratory Medicine Department, Sabah Hospital, and Head of the Histopathology Committee, Ministry of Health. "Digital Pathology will help to improve turnaround times, and therefore give patients faster results."

*The clinical use claims described in the information provided have not been cleared or approved by the U.S. FDA nor are the products available in the United States. 

About Leica Biosystems:  

Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.

Media Contact: Kristin O'Neill Manager, Global Brand Marketing LBS-GlobalMarketing@leicabiosystems.com +1-847-821-3537

SOURCE Leica Biosystems

Read this news on PR Newswire Asia website: Leica Biosystems Aperio Digital Pathology Now Nationwide Standard of Care in Kuwait*

[ebizupdate]

Leica Biosystems Aperio Digital Pathology Now Nationwide Standard of Care in Kuwait*

VISTA, Calif., May 23, 2017 /PRNewswire/ -- Leica Biosystems announced today that it has struck a key partnership with the Kuwait Ministry of Health, through its distributor, Technical Services Supplies Trading & Contracting Company, W.L.L. The Pathology Council of Kuwait will now adopt Leica Biosystems digital pathology as its standard of care. This initiative will create a nationwide pathology network, powered by Aperio ePathology Solutions, linking eight key hospitals and leveraging pathology expertise across the country.

"With one of the most extensive digital pathology initiatives in the world, Kuwait is leading the charge to transform pathology and its critical role in healthcare," said Jerome Clavel, Vice President and General Manager for Leica Biosystems Pathology Imaging. "Our Aperio ePathology Solutions will enable rapid sharing and collaboration. This will reduce the need for pathologists to travel and increase patient access especially in remote locations."

The Kuwait Cancer Control Center (KCCC) has been using Aperio ePathology since 2011, for both national and international slide sharing and collaboration. Building on their experience, the nationwide hub-and-spoke deployment of Aperio ePathology will enable efficient utilization of Kuwait's pathology expertise; providing pathologists with rapid access to slides and cases.

"The full adoption of Aperio ePathology throughout Kuwait is a critical, technological advancement for the pathology workflow. It will make secondary reviews and collaboration easier, faster and more efficient. In the past, shipping of glass slides required 3 to 4 days by itself. Now, subspecialty expertise can be available to remote locations within 24 hours without sending any physical slides," said Dr. Abdullah Akbar, Consultant Pathologist, Head of the Laboratory Medicine Department, Sabah Hospital, and Head of the Histopathology Committee, Ministry of Health. "Digital Pathology will help to improve turnaround times, and therefore give patients faster results."

*The clinical use claims described in the information provided have not been cleared or approved by the U.S. FDA nor are the products available in the United States. 

About Leica Biosystems:  

Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.

Media Contact: Kristin O'Neill Manager, Global Brand Marketing LBS-GlobalMarketing@leicabiosystems.com +1-847-821-3537

SOURCE Leica Biosystems

Read this news on PR Newswire Asia website: Leica Biosystems Aperio Digital Pathology Now Nationwide Standard of Care in Kuwait*

[shelcywalters-blog]

#immunopathology a #vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. Know more @ surgicalpathology.alliedacademies.com

  #pathology #surgicalpathology #conference #meeting #gathering #congress #Paris #France

[shelcywalters-blog]

#epathology One key goal in laboratory medicine is to integrate all patient records, an objective that requires all images to be in an electronic format. Know more @ surgicalpathology.alliedacademies.com

[shelcywalters-blog]

#ePathology is an electronic platform for #pathologists, laboratorians, and other medical and veterinary professionals from all around the world to receive real-time consultation for pathologic diagnosis of suspected cases of infectious diseases.

know more @ http://surgicalpathology.alliedacademies.com/